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Abstract: Hydrogels have become key players in the field of drug delivery owing to their great
versatility in terms of composition and adjustability to various administration routes, from parenteral
(e.g., intravenous) to non-parenteral (e.g., oral, topical) ones. In addition, based on the envisioned
application, the design of bioadhesive or mucoadhesive hydrogels with prolonged residence time
in the administration site may be beneficial. For example, hydrogels are used as wound dressings
and patches for local and systemic therapy. In a similar way, they can be applied in the vaginal
tract for local treatment or in the nasal cavity for a similar goal or, conversely, to target the central
nervous system by the nose-to-brain pathway. Overall, hydrogels have demonstrated outstanding
capabilities to ensure patient compliance, while achieving long-term therapeutic effects. The present
work overviews the most relevant and recent applications of hydrogels in drug delivery with special
emphasis on mucosal routes.
Keywords: hydrogels; drug delivery; bioadhesion and mucoadhesion; oral delivery; topical delivery;
vaginal delivery; rectal delivery; ocular delivery; transdermal delivery
1. Introduction
Hydrogels are hydrophilic viscoelastic materials formed by a polymeric network with physical
and/or chemical crosslinks that absorb and retain large amounts of water (several times their dry
weight) and swell, while maintaining their 3D structure, mechanical strength and elasticity [1–5].
In addition, hydrogels can be easily modified with functional groups and display pores with
well-defined sizes that can be controlled by the crosslinking density and that can be sensitive to
external stimuli such as pH, temperature and magnetic field [6]. In a hydrogel, polymer chains
create a characteristic 3D matrix with interstitial spaces that are capable of harboring aqueous fluids
such as the physiological ones [4]. Moreover, the high water content provides an environment for
the diffusion of oxygen, nutrients and other small molecules that are critical for cell growth and
proliferation [7]. Thus, molecules of different drugs can be incorporated into the hydrogel and diffuse
from the interstitial spaces to the biological medium, allowing their use as a reservoir for controlled
release applications [1]. Therefore, over the years, hydrogels became key players in the biomedical
field in general and pharmaceutical research and development in particular, employing different
invasive and minimally invasive administration routes [8]. Peppas et al. [9] have done an enormous
contribution to the understanding of the mechanisms involved in the release from different systems,
from moderately or poorly swellable [10] to semi-crystalline hydrogels [11].
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The choice of the material for the synthesis of the hydrogel depends on the application and
ranges from fully synthetic polymers such as poly(ethylene glycol) (PEG) and poly(vinyl alcohol)
(PVA) to natural ones such as polysaccharides (e.g., hyaluronic acid, alginate, chitosan) and proteins
(e.g., gelatin) [12,13]. For example, the use of chitosan hydrogel scaffolds for controlled and localized
delivery of drugs that promote wound healing was recently reviewed by Elviri et al. [14].
Hydrogels can be prepared using different methods and precursors that allow the adjustment of
properties such as pore size, mechanical strength, degradability and rate of degradation [13,15]. For
example, Silva et al. [16] reviewed the manufacture and use of hydrogels based on fibrous proteins (e.g.,
silk, keratins, elastin, resilins), which are one of the most versatile biomaterials for tissue engineering.
These scaffolds can be also used as carriers for the localized delivery of growth factors, enzymes, and
drugs (Figure 1).
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Figure 1. Hydrogels and tissue engineering. Schematic diagram of the use of hydrogels in (A) 
microencapsulation and (B) tissue-engineering scaffold. (Reprinted with permission from reference 
[16]. Copyright 2014 Elsevier). 
As explained above, properties of hydrogels such as pore size may be controlled by the 
production conditions and/or the modification of the polymers or the weight ratio between them. 
For example, Zhang et al. [17] studied the properties of PEG diacrylate (PEGDA) hydrogels by 
varying the molecular weight of the precursor (400–2000 g/mol) or the ratio between them (100/0, 
40/20, 30/30, 20/40, 0/100). Systems were photo-polymerized under visible light at a total polymer 
concentration of 60% w/w. Results showed that properties such as swelling, wetting, elastic 
modulus, transparency and microstructure changed when modifying these synthesis parameters. 
An important characteristic of hydrogels is their similarity with the extracellular matrix, thus 
allowing their use as scaffolds for tissue engineering and regenerative medicine [4]. Slaughter et al. 
[18] extensively reviewed the application of hydrogels in regenerative medicine. 
Overall, hydrogels have emerged as an extremely versatile technology platform for tissue 
engineering and drug delivery. In this work, we will overview the development and use of 
polymeric hydrogels for advanced drug delivery systems. Even though the literature is very 
profuse, we will focus mainly on most recent works that introduce new concepts and methods for 
their synthesis, characterization and/or administration. In this context, the field of tissue engineering 
is beyond the scope of the review. At the same time, it is worth stressing that aiming to improve 
tissue regeneration and repair, some researchers used hydrogel scaffolds for the localized delivery of 
a variety of active compounds, from drugs to biologicals. Moreover, the use of some innovative 
hydrogels conceived for tissue engineering could be extended to other biomedical applications, 
including drug delivery. Thus, some examples at the interface of these fields, namely drug delivery 
and tissue engineering, will be also briefly discussed.  
Figure 1. Hydrogels and tissue engineering. Schematic diagram of the use of hydrogels in (A)
microencapsulation and (B) tissue-engineering scaffold. (Reprinted with permission from reference [16].
Copyright 2014 Elsevier).
As explained above, properties of hydrogels such as pore size may be controlled by the production
conditions and/or the modification of the polymers or the weight ratio between them. For example,
Zhang et al. [17] studied the properties of PEG diacrylate (PEGDA) hydrogels by varying the molecular
weight of the precursor (400–2000 g/mol) or the ratio between them (100/0, 40/20, 30/30, 20/40,
0/100). Systems were photo-polymerized under visible light at a total polymer concentration of 60%
w/w. Results showed that properties such as swelling, wetting, elastic modulus, transparency and
microstructure changed when modifying these synthesis parameters.
An important characteristic of hydrogels is their similarity with the extracellular matrix, thus
allowing their use as scaffolds for tissue engineering and regenerative medicine [4]. Slaughter et al. [18]
extensively reviewed the application of hydrogels in regenerative medicine.
Overall, hydrogels have emerged as an extremely versatile technology platform for tissue
engineering and drug delivery. In this work, we will overview the development and use of polymeric
hydrogels for advanced drug delivery systems. Even though the literature is very profuse, we will
focus mainly on most recent works that introduce new concepts and methods for their synthesis,
characterization and/or administration. In this context, the field of tissue engineering is beyond the
scope of the review. At the same time, it is worth stressing that aiming to improve tissue regeneration
and repair, some researchers used hydrogel scaffolds for the localized delivery of a variety of active
compounds, from drugs to biologicals. Moreover, the use of some innovative hydrogels conceived for
tissue engineering could be extended to other biomedical applications, including drug delivery. Thus,
some examples at the interface of these fields, namely drug delivery and tissue engineering, will be
also briefly discussed.
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2. Polymeric Hydrogels for Drug Delivery Applications
An interpenetrating polymer network is a 3D network composed of two or more networks, where
the polymer chains are partially or fully intertwined at a molecular level, but not covalently linked to
each other and thus, they cannot be separated unless chemical bonds are broken. In this sense, Naseri
et al. [19] designed hydrogels of a double cross-linked interpenetrating polymer network based on
cellulose nanocrystals in a matrix of sodium alginate and gelatin by freeze-drying. A homogeneous
solution of sodium alginate and gelatin was mixed with a suspension of nanocrystalline cellulose and
allowed to dry for three days. This dry blend was put in contact with divalent calcium ions (Ca2+)
and then with genipin, a natural aglycone derived from the fruit of Gardenia jasminoides; the former
crosslinks alginate, while the latter gelatin. Finally, samples were lyophilized for 24 h to obtain sponges
for potential use as a substitute for cartilage. Cellulose nanocrystals have garnered much interest in
biomedical applications due to have showed improve the dimensional stability and the mechanical
strength of hydrogels and facilitate the release of drugs.
Hydrogels formed from self-assembled biopolymer networks are particularly interesting in better
mimicking the microenvironment of native tissues as they show structural, chemical and mechanical
similarities to the extracellular matrix and good biological compatibility. Tissue engineering scaffolds
play a fundamental role in providing a native environment that mimics tissues for the cells, with the aim
of promoting regeneration of the desired tissue [16]. One of the main applications of hydrogels is the
treatment of wounds, an application that usually demands the use of biomaterials that promote tissue
repair or regeneration and prevent infections. In this context, Straccia et al. [20] developed alginate
hydrogels coated with chitosan as wound dressing. The coating was used to confer antibacterial
activity and to delay the release of charged hydrophilic drugs into the alginate (Figure 2).
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Figure 2. Preparation of alginate hydrogels coated with chitosan for wound dressing. (Reprinted 
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All the coated hydrogels retained their transparency, a desirable feature in wound dressings 
that allows visual inspection of the lesion bed throughout the healing process. In vitro assays with 
human mesenchymal stromal cells (MSC) confirmed the absence of acute toxicity of the coating 
biomaterial (Figure 3) [20]. 
The release characteristics were assayed using rhodamine B as the hydrophilic model drug and 
compared with that of the uncoated counterparts. The presence of the chitosan coating served as a 
Figure 2. Preparation of alginate hydrogels coated with chitosan for wound dressing. (Reprinted from
reference [20]).
All the coated hydrogels retained their transparency, a desirable feature in wound dressings that
allows visual inspection of the lesion bed throughout the healing process. In vitro assays with human
mesenchymal stromal cells (MSC) confirmed the absence of acute toxicity of the coating biomaterial
(Figure 3) [20].
The release characteristics were assayed using rhodamine B as the hydrophilic model drug and
compared with that of the uncoated counterparts. The presence of the chitosan coating served as
a barrier that delayed the diffusion of rhodamine B and, therefore, resulted in a decrease of the release
kinetics. Finally, the antibacterial activity of coated hydrogels against Escherichia coli was demonstrated.
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Figure 3. (a,b) Microscopic images of mesenchymal stromal cells (MSC)) cultured for seven days in
control culture medium after crystal violet staining; (c,d) microscopic images of MSC cultured for
seven days in 0.1% chitosan hydrochloride culture medium after crystal violet staining. (Reprinted
from reference [20]).
Currently, new biomaterials modified with cyclodextrins (CDs) are being investigated as
advanced deliv ry systems for both hydrophilic and hydrophobic drugs [21]. CDs are natural cyclic
oligosaccharides consisting of α-D-glucopyranose units joined by α-1,4-type bonds and provided
with a central lipophilic cavity and a hydrophilic outer surface that allow the formation of inclusion
or non-inclusion complexes, thus improving the physicochemical properties of drugs, in particular,
those displaying low aqueous solubility. This ability can be imparted to polymer networks in which
the CDs ar chemically grafted or cross-linked [22]. The combination of CDs and hydrogels in one
single biomaterial leads to synergistic properties: the hydrophilic polymer network improves the
biocompatibility and prevents dilution in the physiological environment, increasing the stability of
the complexes, while CDs provide a more controlled release of the active cargo [7]. For example,
Mennini et al. [23] developed CD-containing ethyleneglycol diglycidyl ether hydrogels for vaginal
administration of dehydroepiandrosterone in the treatment of postmenopausal symptoms. Ovules
combined the controll d relea e an mucoadhesion properties of the hydrogel, and the dissolution
capacity of the CD to overcome its low bioavailability associated with poor aqueous solubility.
3. Preformed Hydrogels versus Hydrogels Formed Upon Implantation (In Situ)
In early y ars, most hydrogels intended for d ug delivery were produced prior to administration
(known as preformed hydrogels) and depending on their size (macroscopic or microscopic), they were
administered by invasive or minimally invasive procedures. In other words, preformed hydrogels are
simple viscous solutions or films, which gel outside the body and do not undergo a modification of
their properties (e.g., rheological or mechanical) after administration. More recently, the development
of systems that are deployable in the body as liquids or semi-solids and undergo a transition to
solidify in situ emerged as a very appealing strategy to ensure patient compliance and comfort [24].
Different mechanisms can be exploited to achieve the transition, from in situ polymerization by
photo-initiated reactions to the use of stimuli-responsive polymers that change their properties
in response to changes in temperature, pH, and ionic strength, under physiological conditions.
In addition, hydrogels may respond to externally applied stimuli such as ultrasound, electromagnetic
field or light that may be employed to release the cargo with modified kinetics (e.g., pulsatile release).
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In this context, Tsitsilianis [25] reviewed stimuli-responsive reversible hydrogels with tunable gel
properties, such as injectability and responsiveness, mesh size, mechanical strength and dynamics.
These hydrogels provide promising platforms for the encapsulation and delivery of drugs and cells
in a variety of biomedical applications [1,26–28]. For example, one of the most widely exploited
polymers for the synthesis of in situ formed hydrogels used in the delivery of drugs are poly(ethylene
oxide)-b-poly(propylene oxide) (PEO-PPO) block copolymers known as poloxamers or Pluronic®
(linear and bifunctional) and poloxamines or Tetronic® (branched and tetrafunctional) [29]. Due to
their amphiphilic nature, these copolymers can self-assemble and form spherical polymeric micelles
in aqueous solution above the critical micellar concentration (CMC). In addition, above the critical
concentration and temperature of gelation, the self-assembled polymeric micelles are tightly bound to
produce a physically cross-linked hydrogel structure [30–32]. Figure 4 shows the structure of polymeric
micelles made of Pluronic® copolymers and their gelation once the concentration is increased [32].
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Thus, these systems exhibit sol-gel transition properties in response to temperature in aqueous 
solution usually around the physiological temperature and, therefore, they can be administered as 
liquids at room temperature and undergo gelation at body temperature. In addition, the gelation 
temperature of these formulations decreases with a concentration increase [31]. It is worth stressing 
that high copolymer concentration is usually required to form the gel. For example, 25% w/v 
poloxamers are required to form a rigid gel after ocular instillation [33]. Moreover, regardless of the 
concentration, the micro-viscosity properties are relatively poor, which causes fast dilution in the 
biological fluids and release of the payload (Figure 5) [34] and eventually elimination from the 
administration site, especially in those with significant biological fluid flow (e.g., mouth, vagina).  
Figure 4. Schematic representations of Pluronic® F127 micelles: (a) single micelle with spherical
core-shell geometry; (b) single 2D hexagonally packed layer of micelles; (c) two 2D hexagonally packed
layers of micelles (AB); and (d) three laye s with ABC (o Faced Centered Cubic, FCC) stacking sequence
structure. (b–d) correspond to t e radial geometry. (Reprin ed with permission from reference [32].
Copyright 2007 American Chemical Society).
Thus, these systems exhibit sol-gel transition properties in response to temperature in aqueous
solution usually around the physiologi al t mper ture and, therefore, they can be administered as
liquids at room temperature and undergo gelation at body te perature. In addition, the gelation
temperature of these formulations decreases with a concentration increase [31]. It is worth stressing that
high copolymer concentration is usually required to form the gel. For example, 25% w/v poloxamers
are required to form a rigid gel after ocular instillation [33]. Moreover, regardless of the concentration,
the micro-viscosity properties are relatively poor, which causes fast dilution in the biological fluids
and release of the payload (Figure 5) [34] and eventually elimination from the administration site,
especially in those with significant biological fluid flow (e.g., mouth, vagina).Gels 2017, 3, 25  6 of 22 
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Aiming to reduce the copolymer content and improve the gelation properties, these gel-forming
biomaterials were modified [35,36]. For example, Cohn et al. [37] polymerized poloxamer precursors
and increased their molecular weight, resulting in a dramatic improvement of the rheological properties
and the physical stability in aqueous media. In addition, it was found that a reduction in the
concentration of the gel-forming copolymer could be achieved by the incorporation of a suitable
viscosity-enhancing polymer [38].
3.1. Preformed Hydrogels
As mentioned above, preformed hydrogels constitute the first generation and have been
extensively explored in biomedical applications in general, and drug release in particular. This
review does not attempt to be a comprehensive compendium of all the literature on the subject and,
therefore, some recent works of especial interest are briefly described. Huang et al. [39] obtained
a hybrid hydrogel membrane composed of carboxymethylcellulose (CMC) enriched with berberine
(anti-inflammatory and antimicrobial agent) and hyaluronic acid to be used as an anti-adhesive barrier
and drug delivery system with excellent anti-inflammatory and tissue regeneration properties to
prevent post-surgical adhesions. PVA, the surfactant Tween® 80 and a natural oil were added as
membrane-forming agent, emulsifier and lubricant, respectively. The homogenous mixture was placed
in a mold and subjected to heating at 37 ◦C for 3 h to form a dry membrane. A hydrogel of CMC (loaded
with berberine) and hyaluronic acid in a ratio of 30:70 presented optimal plasticity and inhibited 60%
of lipopolysaccharide-stimulated inflammation in RAW264.7 macrophages in vitro.
Preformed hydrogels can also be injected as solids [40]. In this case, the solid system can be
“thinned” by applying a sufficiently high shear stress and thus, reduce its viscosity. Once at the
implantation site and the stress being eliminated, the material immediately recovers the original
mechanical properties of the solid. Thus, these drug delivery systems become a more benign
treatment when compared to conventional surgery that involves tissue damage and later suture.
Due to this property, shear thinning and thixotropic systems are often included in the category of
injectable biomaterials [40]. Recently, Riber et al. [41] developed a new technology as a drug delivery
platform consisting of a network of interpenetrating silicone hydrogel polymers impregnated with
a broad-spectrum antimicrobial compound such as irgasan, to eliminate plasmids. The spread of
antimicrobial resistance, generally mediated by the horizontal transfer of plasmids, limits treatment
options for bacterial infections. Exposure of bacteria (e.g., Escherichia coli K-12) to this interpenetrating
network for 24 h resulted in a significant loss of plasmid (2.8–4.7%) (p < 0.05). To further increase the
plasmid loss, the concentration of impregnated irgasan should be increased, or conversely, a constant
exposure ensured over time. Both options would likely result in severely damaged cell growth
conditions and the formation of an adaptive response leading to the development of drug resistance,
suggesting the limitations of this compound in future therapeutic and medical applications. However,
as a drug delivery device, the hydrogel portion of the matrix network extends the range of drugs that
can be transported, stored and subsequently released, including both hydrophilic molecules such as
silver ion complexes, sulfonamides and antimicrobial peptides as hydrophobic compounds.
Hydrogel-based contact lenses can also be designed using suitable polymers. For example,
Tummala et al. [42] developed a highly transparent hydrogel with high water content (>90%) by
combining PVA with nanocellulose (NC) to obtain model contact lenses without compromising their
transparency. NC was used to strengthen the PVA hydrogel and facilitate the manipulation of the lenses.
Hydrogels showed a refractive index close to that of pure water, high transparency to visible light and
very good blocking properties to ultraviolet radiation. In addition, they were rigid and flexible enough
to adapt well to a convex surface such as the eye and exhibit high elasticity without being ruptured
under stretching. The high water content can favor optical transparency, give good comfort of use, high
oxygen permeability, low protein deposition and high biocompatibility. The hygroscopic nature of NC
could also contribute to the retention of water over time, a fundamental property for a medical device
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that is exposed to air. With the introduction of additional molecular features (e.g., modification with
CDs), this work appears as a platform of value for the development of medicated contact lenses [43].
3.2. Hydrogels Formed In Situ
As discussed above, in situ generated hydrogels are liquid at the administration time and display
a transition due to structural changes induced by external stimuli or in the biological environment [44].
This approach is very advantageous, for example, in ocular delivery as these vehicles can be easily
applied as a liquid that ensures complete coverage of the eye being stabilized in situ due to gelation,
in contrast to pre-gelled formulations that show lower adjustability [1]. In addition, in a minimally
invasive manner, a liquid can be injected for in situ formation of a matrix in the development of
injectable intraocular lenses [17]. Following this conceptual approach, Anumolu et al. [1] developed
fast crosslinking thiolated PEG hydrogels that are stabilized at physiological pH via S-S bonds. Then,
these stable viscoelastic hydrogels were loaded with pilocarpine for controlled ocular delivery and
subsequent pupillary constriction. In vivo studies in rabbits showed that the hydrogels ensured
pupillary constriction for 24 h after administration, eight times more than an aqueous solution of the
same drug (Figure 6).
1 
 
 
Figure 6. Correlation between in vitro pilocarpine release and pupillary constriction obtained in vivo.
A linear correlation is evident with an R2 of 0.97. As the amount of pilocarpine available for absorption
decreases, a corresponding increase in pupil diameter is observed. Data are reported as mean ± SEM.
Solid line indicates the best-fit line and dashed line indicates the 95% confidence interval. (Reprinted
with permission from reference [1]. Copyright 2009 Elsevier).
The same research group developed in situ-forming biodegradable hydrogels based on PEG
loaded with the bacteriostatic drug doxycycline for the healing of vesicant-induced ocular wounds
in rabbit [45]. The hydrogels withstood shear forces and released the cargo (0.25% w/w) following
a bimodal profile with 100% release over one week. The permeation of doxycycline through vesicant
wounded corneas was between 2.5- and 3.4-fold higher than in unwounded corneas. Moreover,
histology and immunofluorescence studies confirmed a significant decrease of the collagenase matrix
metalloproteinase-9 and an improvement of the healing process in vesicant-exposed corneas compared
to the free drug delivered in phosphate buffered saline of pH 7.4 (Figure 7).
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i r 7. Hematoxylin and Eosin staining to visualize the histology of CEES and NM-exposed corneas
treat d for 24 h with doxycycline in solution or in a hydrogel. The damaged area is where the epithelium
meets the stroma. The w und-healing efficacy of doxycycline s lution was close to the doxycyclin
hydrogel for CEES exposed corneas, as the extent of damage was comparatively mild. However,
a superior wound healing efficacy was observed with hydrogels over solutions when harshly damaged
NM-exposed corneas were treated with doxycycline. CEES: half mustard; NM: mustard; DOXY:
doxycycline. (Reprinted with permission from reference [45]. Copyright 2010 Elsevier).
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The regeneration of injured peripheral nerves represents a great challenge for the clinic and it
requires the use of scaffolds [46]. Biocompatible hydrogels loaded with drugs could play a fundamental
role in this sense because they could be used to accelerate the regenerative process. Guo et al. [47]
developed a chitosan conduit containing simvastatin (25 and 50 mg/mL) in Pluronic® F127 hydrogel
(25% w/v) to bind defects in the sciatic nerve of rats. The poloxamer solution is injected into the
chitosan conduits and undergoes a phase transition at 37 ◦C. Preclinical studies in rats showed
an improvement in peripheral nerve regeneration with recovery of the functionality. It is important to
highlight that injured nerves treated with the drug-loaded hydrogel and the conduit were thicker than
controls treated with the hollow duct or with the hydrogel-filled duct without simvastatin, 10 weeks
post-surgery. This performance might rely on the increase of the expression of several endogenous
neurotrophic factors that has been ascribed to simvastatin.
Regardless of the appeal shown by these systems, it is noteworthy that even though in situ-forming
hydrogels can more easily fill well-defined defects and cavities, their free flowing properties may
lead to undesired leakage of these precursor solutions into the surrounding tissue or into the
bloodstream, unless the defect has well-defined boundaries and the precursor is confined in it until its
solidification [40].
Smart Hydrogels
The various therapeutic challenges and the improvement of treatment standards led researchers
in both academia and industry to devote efforts towards the design and development of “smart”
biomaterials in general and hydrogels in particular. The rationale behind them is that they can
interplay with the biological environment in a pre-programmed way and thus, display changes in
some of their properties (e.g., viscosity) [4] in response to pH, temperature, electric and magnetic fields,
among others [44,48,49].
Gupta et al. [26] used the triblock copolymer poly[(propylenesulfide)-(N,N-dimethylacrylamide)-
(N-isopropylacrylamide)] to form temperature-sensitive hydrogel endowed with a drug degradation
and release mechanism in response to reactive oxygen species (ROS) in vitro (Figure 8).
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Figure 8. Concept behind hydrogels of poly[(propylenesulfide) (PPS)-(N,N-dimethylacrylamide) 
(DMA)-(N-isopropylacrylamide) (PNIPAAM) that undergo reversible gelation at 37 °C and degrade 
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Figure 8. Concept behind hydrogels of poly[(propylenesulfide) (PPS)-(N,N-dimethylacrylamide)
(DMA)-(N-isopropylacrylamide) (PNIPAAM) that undergo reversible gelation at 37 ◦C and degrade
upon exposure to ROS. (Reprinted with permission from reference [26]. Copyright 2014 American
Chemical Society).
When the hydrogel is exposed to ROS, it slowly undergoes a transition to a more hydrophilic
poly(propylene sulfide), and finally to a poly(propylsulfone) that triggers the sustained release of
drugs “on demand” and subsequent degradation of the hydrogel. In addition, these hydrogels can
be used for the encapsulation and release of cells because they possess inherent cellular protection
properties and reduce ROS-mediated cell death in vitro [26].
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The synthesis of vehicles that are sensitive to intracellular stimuli is also gaining popularity.
These transporters can be created by incorporating various precursors into the hydrogel [15]. Recently,
heparin-bound Pluronic® F127 thermo-sensitive hydrogels that load and release acid fibroblast growth
factor (aFCF) were used to treat spinal cord injuries (SCIs) [50]. Heparin was added to increase the
loading of aFCF, to stabilize its structure, to protect its activity and to control the release. Preclinical
studies in rats with SCI showed that animals that were administered the aFCF-loaded heparin-based
hydrogel had attenuated disruption of the blood-spinal cord barrier (BSCB), reduction of neuronal
apoptosis, production of reactive astrogliosis and increased neuronal and axonal rehabilitation with
respect to controls without growth factor or free growth factor administered by the intravenous route
(Figure 9) [50].
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Figure 9. Schematic of aFGF-heparin (HP) thermo-sensitive hydrogels enhance the recovery of
spinal cord injury (SCI). The protection of aFGF-HP containing blood-spinal cord barrier (BSCB)
protection, neuroprotection, remyelination, attenuation of astrogliosis, axon elongation in three different
stages after SCI, which are the main obstacles to recovery of SCI. (Reprinted with permission from
reference [50]. Copyright 2017 American Chemical Society).
Gels 2017, 3, 25 11 of 22
4. Nanogels and Microgels
The development of nanometer-sized hydrogels (nanogels) has attracted the attention of
researchers because of their great biomedical potential in drug administration and diagnostics [51].
In addition, this nanotechnology platform can be combined with others to synthesize more complex
systems. For example, Mekkawy et al. [52] synthesized silver nanoparticles in the 13–19 nm size
range and subsequently coated them with PEG 6000, sodium dodecyl sulfate and β-CD (Figure 10).
Then, they studied the antibacterial activity against Gram-positive (e.g., Staphylococcus aureus) and
Gram-negative (e.g., Escherichia coli) bacteria. The values of minimum inhibitory concentration (MIC)
and minimum bactericidal concentration (MBC) were in the range of 0.93-7.5 and 3.75-15 µg/mL,
respectively, that were lower than those reported in the literature. Then, hydrogels loaded with coated
silver nanoparticles were prepared by dispersing the same in gelling agents such as sodium CMC,
sodium alginate, HPMC, Pluronic® F127 and chitosan.
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hydrogels loaded with PEG-coated silver nanoparticles with respect to a commercially available 
sulfadiazine cream (Figure 11) [52]. 
Figure 10. Representative TEM micrographs for the aqueous dried AgNPs (100 µg AgNPs/mL):
(A) uncoated AgNPs; (B) SDS-coated AgNPs; (C) PEG-coated AgNPs (×100,000); (D) β-CD-coated
AgNPs (×140,000) with sizes = 15.7 ± 4.8, 13 ± 4, 19.2 ± 3.6, and 14 ± 4.4 nm, respectively (n = 50,
bar represents 100 nm). Insets indicate histograms of AgNPs size distribution. Abbreviations: TE ,
trans ission electron icroscopy; g Ps, silver nanoparticles; S S, sodiu dodecyl sulfate; PE ,
polyethylene glycol; β- , β-cyclodextrin. (Reprinted fro reference [52]).
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In vivo results indicated higher antibacterial activity and wound healing capacity of CMC
hydrogels loaded with PEG-coated silver nanoparticles with respect to a commercially available
sulfadiazine cream (Figure 11) [52].Gels 2017, 3, 25  12 of 22 
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Figure 11. Successive images of representative mice skin abrasion wounds infected with MRSA at
different time intervals. Two groups were treated with 0.1% silver nanoparticles (AgNPs) hydrogel
and 1% silver sulfadiazine cream. The two other groups were the blank hydrogel-treated group and
control untreated mice. Abbreviations: MRSA, methicillin-resistant Staphylococcus aureus; AgNPs, silver
nanoparticles. (Reprinted from reference [52]).
Another strategy to capitalize on advantageous features of nanotechnology and drug
delivery systems at the macro scale is the development of hydrogels formed by self-assembled
nanoparticles. In this case, the drug-loaded nanoparticles self-aggregate giving rise to
a hierarchical macroscopic hydrogel. After administration, the nanoparticles undergo dissociation
and diffuse freely in the physiological milieu, maintaining the favorable characteristics of
the nanometric size as a large surface area and easy access to the intracellular space by
means of endocytosis. For example, Huang et al. [53] developed nanoparticles made
of an (epsilon-caprolactone-co-1,4,8-trioxa[4.6]spiro-9-undecanone)-PEG-poly(epsilon-caprolactone)
copolymer loaded with the anti-cancer drug doxorubicin as model drug for peritumoral chemotherapy.
In vivo results showed that one single peritumoral injection was more effective in a murine model
than multiple intravenous administrations of the free drug and drug-free nanoparticles. This indicated
that hydrogels could sustain the release and thus, reduce the administration frequency and minimize
systemic toxicity [53].
The combination of microtechnology with hydrogels is also an interesting field for obtaining
improved drug delivery systems. Combination strategies may be based on spherical or fiber-like
microparticles of hydrogels or microparticles incorporated within macroscopic hydrogels using
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different techniques. For example, Ahmad et al. [54] synthesized hydrogels of bacterial cellulose
graft copolymers with poly(acrylic acid) by electron beam irradiation. The resulting hydrogel sheets
were oven dried at 60 ◦C until constant weight. Then, microparticles were prepared from the hydrogel
by grinding and milling the purified sheets. Subsequently, the microparticles were loaded with insulin
solution (0.5 mg/mL), filtered and lyophilized. Results showed that the microparticles increased up
to 5.9 times the paracellular transport of insulin across the Caco-2/HT29-MTX monolayer model of
the intestinal epithelium in vitro when compared to an insulin solution. In addition, insulin-loaded
microparticles showed a greater hypoglycemic effect and an increase in relative oral bioavailability of
up to 7.45-fold with respect to an insulin solution after oral administration in diabetic rats [54].
5. Administration Routes of Hydrogels
Hydrogels have found application in different minimally invasive and invasive administration
routes. In the next sections, we will exemplify the great versatility of this technological platform in
pharmaceutical development.
5.1. Minimally-Invasive Administration Routes
Buccal administration is becoming a very popular administration route owing to numerous
advantages, including the entry of the drug into the systemic circulation and self-administration.
However, it requires the appropriate design of the delivery system to maintain its position in the mouth
avoiding involuntary ingestion and minimizing the continuous dilution of the drug by the salivary
flow. In this sense, hydrogels may be a suitable drug delivery system by this route [55]. For example,
Choi et al. [31] developed a thermo-responsive oral mucoadhesive hydrogel for the administration
of the anti-cancer drug paclitaxel in the oral mucosa that provides a high local concentration of the
drug and it is intended to decrease the systemic side effects normally associated with the intravenous
administration. The formulation consisted of a dimethyl-β-CD/paclitaxel inclusion complex which
improves drug solubility within a physical hydrogel of Pluronic® F127 with mucoadhesive and
sustained release properties. The cytotoxicity of the gels loaded with the inclusion complex was
evaluated by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay using
human oral cancer cells (KB cells, a subline of the ubiquitous keratin-forming tumor cell line HeLa).
The lowest cell viability was >80% for hydrogels without drug, suggesting that they are not cytotoxic
for KB cells. However, the cellular viability of drug hydrogels was considerably lower due to intact
paclitaxel cytotoxicity. Since the formulation undergoes gelation at 37 ◦C, it emerges as a promising
approach to treat several oral cancers with reduced systemic toxicity [31].
The oral route is very advantageous over injectable administration due to better patient comfort
and compliance and provides a large absorption surface [56]. In this context, Dafe et al. [57]
developed a hydrogel made of food grade starch/pectin for the encapsulation and colonic release
of the probiotic bacterium Lactobacillus plantarum that was encapsulated by the extrusion method.
Results demonstrated that the encapsulated cells are resistant to adverse conditions of the simulated
gastrointestinal tract and to a bile salt solution as compared to free ones. Then, at more neutral pH
conditions that mimic the colon fluids, cells were released and proliferated (Figure 12).
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The oral administration of peptides and proteins has become a great challenge in pharmaceutical
research [58,59]. In this context, O’Connor et al. [60] developed and characterized systems made of
methacrylic acid (MAA), N-vinyl pyrrolidone (NVP) and PEG monomethyl ether monomethacrylate
(PEGMMA) for the oral delivery of two proteins of different molecular weight, namely insulin and
porcine growth hormone. These terpolymer hydrogels are sensitive to different pH conditions. Thus,
at pH values <4.8 (e.g., stomach), the carboxylic acid group of MMA is protonated, maintaining the
hydrogel in a collapsed state capable of protecting and preventing the release of the encapsulated
proteins. As the pH rises above 4.8, as in the small intestine, the carboxylic acid groups are
deprotonated, allowing the system to swell and release the therapeutic payload. In addition, these
hydrogels exhibit promising mucoadhesive properties for interaction with the lining of the upper small
intestine mucosa. Finally, the compatibility of the hydrogels in two model intestinal cell lines (colon
adenocarcinoma cells, Caco-2, and mature differentiated goblet cells, HT29-MTX) was investigated
and a cytotoxicity of at least 2.5 mg/mL was found [60]. More recently, Treenate and Monvisade [61]
developed a pH-sensitive hydrogel of hydroxyethylacryl chitosan and sodium alginate cross-linked
with different divalent cationic cross-linkers such as Ca2+, Zn2+ and Cu2+, and used paracetamol as
water-soluble model drug. Findings indicated that this combination delayed the degradation time of
the hydrogel and that the amount of paracetamol released in the simulated gastric fluid is relatively
Gels 2017, 3, 25 15 of 22
low (<20%) (Figure 13). Thus, this drug delivery system could be used in site-specific release, such as
in small intestine or colon.
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Figure 13. Percentages of paracetamol release from the hydroxyethylacryl chitosan (HC)/sodium
alginate (SA) hydrogels after immersing in simulated gastric fluid (SGF) for 2 h followed by simulated
intestinal fluid (SIF) for 6 h at 37 ◦C: (a) varying ratios of HC to SA and (b) HC50SA50 with varying
cross-linker types). (Reprinted with permission from reference [61]. Copyright 2017 Elsevier).
Currently, the development of new strategies to increase the residence time of the active substances
is a field of constant research in ophthalmic delivery because conventional formulations such as eye
drops are easily removed by nasolacrimal drainage and >90% of the drug is lost. Thus, the use of
semi-solid formulations that display longer residence time in the corneal surface could be an effective
strategy [62]. For example, Huang et al. [63] developed an ophthalmic drug delivery system based
on an in situ gelation hydrogel of Pluronic F127® (22% w/v) and Pluronic® F68 (3.5% w/v) loaded
with betaxolol hydrochloride, a beta blocker used in the treatment of glaucoma. Pharmacokinetic and
pharmacodynamic assays in rabbits indicated that the formulation improves the bioavailability and
significantly lowers the intraocular pressure with respect to the free drug. Recently, Fabiano et al. [64]
developed a thermo-sensitive hydrogel containing mucoadhesive chitosan nanoparticles loaded with
5-fluorouracil for transcorneal administration in the treatment of ocular cancer. The hydrogel could be
instilled as drops allowing easy administration and precise dosing. After instillation, the solution gels
fast at the temperature of the eye (35 ◦C). In addition, nanoparticles promoted transcorneal penetration
of 5-fluorouracil, at least based on studies in rabbits by aqueous humor analysis. Moreover, the
thermo-sensitive hydrogel increased the area-under-the-curve (AUC) between 0 and 8 h, 3.5 times
compared to clear eye drops. The maximum drug concentration from the hydrogel with nanoparticles
reaches a plateau (0.25–0.3 µg/mL) in a time interval of 0.5 to 7 h, due to the ability of the hydrogel to
control the release of the drug following zero-order absorption kinetics [64].
The nasal mucosa has become an appealing administration route not only for local treatments
(e.g., allergies) but also for systemic delivery because it is self-administered, it does not require sterility
and it is virtually painless. From a pharmacokinetic point of view, absorption is rapid due to the
existence of a rich vascularization and a highly permeable structure within the nasal membranes
and it also surpasses hepatic first-pass metabolism [65]. An additional advantage is that depending
on the administration site in the nose, drugs could follow the nose-to-brain pathway, a transport
that is favored for nanoparticles and that overcomes the presence blood-brain barrier that prevents
the arrival of many drugs from the systemic circulation [66]. In this framework, Khan et al. [67]
developed in situ gelling formulations using chitosan and hydroxypropyl methylcellulose (HPMC)
for the intranasal administration of ropinirole, a drug used in the treatment of Parkinson’s disease,
with the objective of its direct arrival in the brain. In vivo bioavailability and brain uptake assays were
Gels 2017, 3, 25 16 of 22
performed in albino rats following intranasal gel administration with ropinirole-99mTc, an intranasal
ropinirole solution and an intravenous ropinirole solution. The absolute bioavailability of the drug
from the in situ gel formulation was 82%. The AUC value in the brain after administration of the gel
in situ between 0 and 480 min was 8.5 times greater than that obtained intravenously and 3 times
higher than that obtained with the solution of the intranasal drug. This confirmed that the nose-brain
transport of the gel formulation in situ with ropinirole could represent a breakthrough in the treatment
of Parkinson’s disease [67]. However, it is important to note that the site of administration within
the nasal cavity should be appropriate to favor passage into the central nervous system and reduce
passage through systemic pathways. On the other hand, Mahajan and Gattani [68] obtained in situ gels
of metoclopramide hydrochloride, a potent antiemetic, for intranasal administration. The gels were
prepared using different ratios of gellan gum, carbopol 934 P and mannitol. In vitro drug permeation
studies across the nasal sheep mucosa showed that the effective passage way could be increased using
a formulation with 0.15% w/v carbopol or more. In addition, histological examination confirmed no
mucosal damage during in vitro permeability studies. Finally, the bioavailability assay of the drug in
rabbits showed a significant increase from 40.7% in the case of the drug in solution to 54.6% in the case
of the gel [68].
The skin is an attractive and accessible route for the systemic administration of drugs from
matrices such as those formed by hydrogels, but the presence of the stratum corneum should be
surpassed to ensure efficient absorption. For example, Arafa and Ayoub [69] designed a hydrogel of
HPMC and carbopol 934 loaded with cholesterol niosomes and Span® 60 loaded with pregabalin to
prevent or diminish the adverse effects produced by the drug after oral administration. Pregabalin is
a drug used in fibromyalgia syndrome and acute pains such as sciatic neuralgia. However, it produces
many adverse effects such as dizziness, drowsiness, dry mouth, blurred vision, difficulty concentrating,
hypersensitivity and decreased platelet count. The parameters of the hydrogel were optimized using
an experimental design. In vitro release assays evidenced a pattern of controlled release. In addition,
the study of permeation in excised skin of rats using Franz diffusion cells showed that the passage of
drug-loaded niosomes was significantly greater than the conventional pregabalin hydrogels [69].
The vaginal route is an excellent route for both systemic and local applications since
gastrointestinal fluids and first-pass liver metabolism are bypassed. In addition, dense vascularization
and high mucosal permeability make this pathway widely used for the administration of many drugs
such as hormones, peptides, antimicrobials and antifungals, among others [70]. In this framework,
Malli et al. [71] designed a thermo-sensitive and mucoadhesive hydrogel of Pluronic® F127 and
chitosan containing metronidazole for topical application to the vaginal mucosa to treat infections by
the protozoan microorganism Trichomonas vaginalis. This topical administration system could reduce
the adverse effects produced by the drug in standard oral therapy because as it limits the absorption
through the vaginal mucosa, while preserving its antiparasitic activity. In addition, the mucoadhesive
properties of the hydrogel controlled the release over time ensuring a more prolonged activity and
gelation in situ facilitates self-administration of a liquid capable of achieving better coverage of the
vaginal mucosa that becomes semisolid at body temperature. The accumulated absorption of the
drug through ex vivo pig vaginal mucosa mounted on a Franz diffusion cell presented a reduction
with respect to the drug in solution and thus, it is expected to result in less systemic adverse effects.
Finally, the activity of metronidazole formulated in the hydrogel was preserved since the viability
curve evaluated in vitro was similar to the free counterpart [71]. Vaginal microbicidal hydrogels
could be a barrier against viral infections and prevent the spreading of the virus through the vaginal
mucosa. In this sense, Bouchemal et al. [72] developed thermo-sensitive hydrogels of Pluronic®
F127 (20% w/w) and HPMC (1% w/w) containing carboxyl groups-modified polystyrene particles
to mimic the size and surface charge of Type 1 human immunodeficiency virus (HIV-1). Analysis
of the trajectories of the fluorescently labeled particles showed that the mobility was decreased by
the hydrogels compared to cervico-vaginal mucus of traditional hydroxyethyl cellulose hydrogels
used as negative controls. In addition, the incorporation of the CD4 M48U1 mini-peptide used as
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an anti-HIV-1 molecule in a mixture of the polymers did not affect its anti-HIV-1 activity as compared
to the conventional hydrogel. Therefore, this type of formulation could be used as a topical microbicide
containing an anti-HIV compound, as it would simultaneously act as a physical and pharmacological
barrier [72].
Another administration route gaining interest is the rectal one because it can reduce the adverse
effects of orally administered drugs, improve patient compliance with respect to injections and be used
in special conditions such as unconscious patients, with difficulty of swallowing or under chronic
therapies where other routes are not possible. It can also be used in local treatments. For example,
Cole et al. [73] developed a 4000 g/mol PEG-based hydrogel in the form of morphine-containing
suppositories for sustained release of the drug following rectal administration. Pharmacokinetic results
in 5 healthy volunteers showed that the drug was released at a constant rate for at least 12 h. This
could improve the pharmacotherapy of patients with chronic pain.
5.2. Invasive Administration Routes
Injectable drug administration involves intravenous, intramuscular, intradermal and
subcutaneous, among others. It may also include intra- or peritumoral administration when the
drug is delivered directly into the tumor or at a site close to it. The drug carriers could be aqueous
or oily according to the route selected. Hereinafter, we will give some examples of drug delivery via
injection of hydrogels.
Chen et al. [30] developed an injectable thermo-responsive hydrogel with mechanical stability
and biocompatibility as a controlled drug delivery vehicle for cancer therapy. The matrix used was
Pluronic® F127 that incorporated hexamethylene diisocyanate links to increase the mechanical stability.
The hydrogel structure was maintained for 30 days ensuring sustained release of the incorporated drug
over an extended period. This copolymer was then added to hyaluronic acid, a natural biocompatible
polymer, to obtain the final nanocomposite hydrogel system that can self-assemble spontaneously
into a micellar structure with a size of 100 to 200 nm. In vitro studies evidenced that the incorporated
drug, doxorubicin, was released for more than 28 days. By using this strategy, the viability of tumor
cells (human breast cancer cells, MCF-7) and tumor size in mice was significantly reduced with the
incubation time [30]. Seib et al. [74] developed self-assembling silk protein hydrogels also loaded
with doxorubicin for the treatment of focal breast cancer and compared this system with the drug
administered intravenously. These hydrogels released the drug for 4 weeks in amounts that could
be precisely adjusted by varying the silk content in the matrix. In addition, its use improved both
the safety and efficacy of the drug. First, the cytotoxicity of doxorubicin-loaded and doxorubicin-free
hydrogels was evaluated using MDA-MB-231 and MCF-7 (human) breast cancer cell lines and 3-day
exposures. The viability of MCF-7 was reduced to 10% after exposure to the free drug and to 20%
for silk hydrogels. For MDA-MB-231 cells, viability was reduced to 23% for all treatment groups.
In addition, a long-term test was performed for 12 days. Control cultures of MDA-MB-231 and
MCF-7 showed exponential cell growth at days 2 to 6 and lower growth over the remaining days.
In contrast, doxorubicin-treated groups showed no or minimal growth during the first 6 days in
the culture. However, they exhibited significant growth over the rest of the study. In contrast,
doxorubicin-loaded hydrogels inhibited cell growth. Regarding efficacy, doxorubicin-loaded hydrogels
administered by bilateral injections near the tumor site showed better antitumor activity than the
equivalent amount of drug administered intravenously. In addition to reducing the primary tumor in
mice with human breast cancer tumor cell xenografts, hydrogels reduced metastasis and were well
tolerated. Thus, two of the five animals treated with doxorubicin-loaded silk hydrogels presented
complete tumor regression, determined by bioluminescence and necropsy. Therefore, this system could
be suitable for local chemotherapy administration and promising in breast cancer therapy to improve
loco-regional control of breast cancer [74]. More recently, Wu et al. [75] developed a thermo-sensitive
hydrogel of cross-linked nanoparticles of poly(vinyl caprolactam)-poly(vinyl acetate)-PEG (known as
Soluplus®) and tacrolimus for local therapy of rheumatoid arthritis. The therapeutic efficacy in rats
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with adjuvant-induced arthritis significantly increased from day 10 to 17 after a single dose of FK-506
loaded in 10% and 20% Soluplus® hydrogels with respect to uncharged hydrogels owing to sustained
drug release and prolonged retention at the injection site.
6. Conclusions and Future Directions
The physical and mechanical properties of hydrogels, together with their biocompatibility and
biodegradability characteristics, have made these materials attractive to a wide range of technological
applications. Adjustment of the hydrogel preparation conditions by varying the different parameters
allows designing suitable systems for potential applications in the fields of drug delivery, tissue
engineering and 3D cell culture and has found its space in the market. The use of “smart” polymers
capable of responding to various stimuli such as changes in pH, temperature, ionic strength or
enzymatic degradation allows administration of polymeric liquids that undergo gelation under
physiological conditions leading to the formation of hydrogels in situ. However, preformed hydrogels
are useful in various applications as wound scaffolds while maintaining the characteristics of
transparency allowing inspection of wounds, as well as the ability to release antimicrobial or
anti-inflammatory drugs and growth factors from their structure by aiding the regeneration of the
tissue. They also allow administration by injection of the solid hydrogel capable of “thinning” during
its administration and subsequent recovery of the mechanical and morphological properties of the
original solid. In addition, hydrogels can be functionalized with a radiopaque that provides X-ray
opacity and allows them to be used as biomedical implants for in vivo visualization and evaluation of
the ability of the hydrogel to prevent postoperative adhesions [76]. As for the administration routes,
hydrogels are very versatile allowing oral, injectable, dermal, vaginal, ophthalmic, and nasal delivery.
In summary, hydrogels represent one of the most versatile technological platforms for pharmaceutical
innovation. On the other hand, the successful bench-to-bedside translation remains elusive and it
is not in accordance with the vast scientific literature probably due to the challenges faced for the
establishment of standardized, scalable and economically viable production processes. This appears as
a critical stage of development that is neglected in most scientific works. Only then, the true potential
of hydrogels could impact the quality of the treatments available for the benefit of patients.
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